Pharmacy News

NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.

Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.

Researchers have created new AI machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.

NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.

The Royal Osteoporosis Society has set up an academy to ultimately to find a cure for osteoporosis.

Researchers are developing a new asthma pill Fevipiprant to target airway muscles to decrease attacks, potentially offering the first new oral treatment for asthma in 20 years.

Earlier this month an event in London - ‘Behind the judging: An exclusive insight into all the major healthcare awards’ - offered a peek into the world of winning a coveted healthcare award.

AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter.

The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study.

AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline, using a unique combination of microfluidics, high-throughput imaging, genomics, deep computing and AI.

The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industry dementia drug discovery collaboration.

ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca's Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma.

New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of various diseases, including cancer.

FDA advisory committees have jointly voted in favour of approving Janssen's Spravato nasal spray CIII for adults living with treatment-resistant depression.

Althea, the Australian medicinal cannabis company, has launched in the UK, following changes allowing specialist doctors to prescribe cannabis-based products for medicinal use to certain patients.

Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival.

The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).

The Peter Sowerby Foundation has issued an open call to source a suitable project for up to £2 million of funding as part of the Foundation’s Health Breakthrough funding strand.

The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published draft guidance on antimicrobial prescribing for hospital-acquired and community-acquired pneumonia, setting out a strategy designed to optimise antibiotic use and reduce antibiotic resistance.

AbbVie has signed a deal with Teneobio to develop a B-cell maturation antigen (BCMA)-targeting bispecific antibody for multiple myeloma.